ASND (Ascendis Pharma AS) Stock Based Compensation: $141 Mil (TTM As of Mar. 2026)


ASND Ascendis Pharma AS ASND
37 GF Score
Price $274.50
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Stock Based Compensation?

Ascendis Pharma AS ASND +2.52% 37 Stock Based Compensation is $141 Mil as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS's Stock Based Compensation for the three months ended in Mar. 2026 was $35 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $141 Mil.

Ascendis Pharma AS Stock Based Compensation Related Terms

Ascendis Pharma AS Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Stock Based Compensation Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.51 67.99 72.69 100.01 136.03

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.63 34.63 35.96 35.08 35.09
ASND
37GF Score
Ascendis Pharma AS ASND
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $141 Mil.

What does a Stock Based Compensation of $141 Mil mean?
Ascendis Pharma AS (ASND) has a Stock Based Compensation of $141 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Stock Based Compensation too high?
Ascendis Pharma AS's current Stock Based Compensation is $141 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Stock Based Compensation compare to JAZZ and BBIO?
Ascendis Pharma AS's Stock Based Compensation of $141 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Stock Based Compensation is $141 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Stock Based Compensation of $141 Mil. The current Stock Based Compensation is $141 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Stock Based Compensation is $141 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$274.50
Price